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ABSTRACT
Purpose. This study was designed to evaluate the beneﬁt
of staging laparoscopy (SL) in patients with suspected hilar
cholangiocarcinoma (HCCA) during the past 10 years.
Only 50–60% of patients with HCCA who undergo lapa-
rotomy are ultimately amenable to a potentially curative
resection. In a previous study, we recommended routine
use of SL to prevent unnecessary laparotomies. The
accuracy of imaging techniques, however, has signiﬁcantly
improved during the past decade, which is likely to impact
the yield and accuracy of SL.
Methods. From 2000 to 2010, 195 patients with suspected
HCCA were analyzed. The yield and accuracy of SL were
calculated by dividing total number of avoided laparoto-
mies by the total number of laparoscopies or by all patients
with unresectable disease, respectively. Factors associated
with better yield and accuracy were assessed.
Results. Of 195 patients with HCCA, 175 underwent SL.
The yield of SL was 14% and the accuracy was 32%.
Operative morbidity of SL was 3%, and operative mor-
bidity of laparotomy for unresectable disease was 33%. No
clear factors that inﬂuenced the yield of SL were found.
Conclusion. Overall yield and accuracy of SL for HCCA
in the present series decreased to 14% and 32%, respec-
tively, compared with earlier reports. This ﬁnding is likely
the result of improved imaging techniques that evolved
during the past decade. The place of SL in the workup of
patients with HCCA needs to be reconsidered, and one
should decide whether the declining additional value of SL
still outweighs the drawbacks of SL.
Hilar cholangiocarcinoma (HCCA), or Klatskin tumor, is
a rare cancer that arises at the conﬂuence of the right and
left hepatic ducts, with an incidence of 2.5 per 100,000.
Radical surgery is the only curative treatment due to
the lack of effective systemic therapy. Many different
imaging techniques, including computed tomography (CT),
abdominal ultrasound (US), percutaneous transhepatic
cholangiography (PTC), endoscopic retrograde cholangio-
pancreatography (ERCP), positron emission tomography
(PET), and magnetic resonance imaging (MRI), are used for
the staging of HCCA. Despite the multitude of diagnostic
tools, only 50–60% of patients who are surgically explored
are ultimately amenable to a potentially curative resection.
1
Peritoneal, nodal, and liver metastases, as well as locally
advanced disease, are the main reasons for unresectability
in patients with HCCA. In an attempt to prevent an
unnecessary laparotomy, staging laparoscopy (SL) has
been performed in patients with HCCA, thereby decreasing
operative morbidity and length of hospital stay associated
with a laparotomy.
2–5 In 2002, we evaluated the use of SL
in patients with malignant proximal bile duct obstruction in
our center and concluded, on the basis of a yield of 42%,
that SL should be performed routinely in the workup for
these patients.
4
The accuracy of radiologic imaging techniques has
continued to improve. Recently, additional techniques,
such as PET and multi-slice CT, have been added to the
staging armamentarium. These advances in staging are
likely to impact the yield and accuracy of SL. Hence, the
purpose of this study was to evaluate the beneﬁt of SL for
staging of patients with suspected hilar cholangiocarci-
noma during the past 10 years in our institution, in which
time imaging modalities have greatly improved.
MATERIALS AND METHODS
All patients presenting with a suspicion on hilar chol-
angiocarcinoma between May 2000 and May 2010 were
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with distal, intrahepatic, and gallbladder cholangiocarci-
noma were excluded from this analysis. All patients had
histological conﬁrmation of their disease.
Staging and Laparoscopy
Patients underwent extensive preoperative imaging,
either performed in the referring hospital or in our own
center. Standard staging examinations included transab-
dominal ultrasound with Doppler imaging of the blood
vessels at the liver hilum, four-phase CT, biliary imaging,
and drainage, by ERCP or PTC. All images from referring
hospitals were revaluated by our own radiologists, who are
experienced in biliary tract morphology. MRI was used
selectively, and PET-CT was performed in most patients
during the past 3 years of the study. After imaging, cases
were reviewed in a multidisciplinary, hepatobiliary meet-
ing and staged according to the modiﬁed Bismuth–Corlette
classiﬁcation based on all available imaging studies.
6 In
addition, other criteria for resectability were taken into
account, such as extrahepatic disease and vascular
involvement. Laparoscopy was planned, when feasible, in
all patients with HCCA Bismuth types 3 and 4 considered
potentially resectable. In patients with HCCA Bismuth
types 1 and 2, staging laparoscopy was performed selec-
tively based on surgeon’s preference.
SL was performed under general anesthesia using three
trocars at umbilical and left and right subcostal position, as
described previously.
7,8 The hepatic surface and peritoneal
cavity were searched for metastases. The hepatoduodenal
ligament and gallbladder were inspected for the presence of
local tumor mass or enlarged lymph nodes. The lesser
omentum was opened and the common hepatic artery
inspected along its course, in search of suspicious lymph
nodes. Biopsies were undertaken under direct vision using
biopsy forceps. Nodal sampling was not performed rou-
tinely, unless a lymph node metastasis was suspected.
Suspected lesions were biopsied and microscopically ana-
lyzed by a pathologist on HE sections. When no metastases
were found, patients were planned for resection. Laparo-
scopic ultrasound was only performed in four patients in
this series and therefore not further analyzed.
Laparotomy and Resection
After laparotomy, the abdomen was inspected for peri-
toneal seeding, distant metastases, or lymph node involve-
ment outside the liver hilum. Suspicious lesions were
excised or biopsied and analyzed by frozen-section his-
tology. Tumors were considered unresectable when the
following signs were found: peritoneal metastases, hepatic
metastases, nodal metastases outside the hepatoduodenal
ligament, or locally advanced disease with tumor inﬁltrat-
ing high up into the segmental bile ducts of both
hemilivers.
9 If more causes of unresectability were found,
the one discovered ﬁrst was reported. More speciﬁcally,
peritoneal metastases, liver metastases, positive lymph
nodes, and locally advanced disease were reported in
decreasing order. In case of metastasis, no further surgical
intervention was performed. In few selected cases diag-
nosed as Bismuth type I and II tumors with locally
advanced disease, a palliative local hilar resection was
performed. In patients with unresectable disease, biliary
drainage was accomplished by deﬁnitive internal stenting
by PTC or ERCP using metal expandable stents, usually
within the same hospital admission.
10,11
The Modiﬁed Clavien-Dindo system was used to grade
complications; grades I and II represented minor and
grades III, IV, and V represented major complications.
12
Statistical Analysis
Patient demographics, preoperative imaging, preopera-
tive Bismuth classiﬁcation, surgical ﬁndings, resectability,
and length of hospital stay were analyzed. The yield of
laparoscopy was calculated by dividing the number of
avoided laparotomies by the total number of laparoscopies.
Accuracy was determined by dividing the number of avoi-
ded laparotomies by all patients with unresectable disease.
Possible factors correlating with accuracy and yield were
veriﬁed by using a chi-square test or Fishers exact test when
numbers in a category were low. The association of dif-
ferent time periods was examined using a test for trend
across groups. Statistical analysis was performed by using
SPSS version 16.0 software (SPSS Inc. Chicago, IL).
P values\0.05 were considered statistically signiﬁcant.
RESULTS
Patient Demographics and Preoperative Imaging
A total of 195 patients were considered resectable based
on imaging and were subsequently surgically treated in our
center. Twenty patients underwent immediate laparotomy
without a SL. Fourteen of these patients had Bismuth type
1 or 2 tumors. In the six other patients, the reason for
omitting laparoscopy was predominantly a doubtful diag-
nosis of malignancy.
A total of 175 patients underwent a staging laparoscopy
and are analyzed in this study. In ten patients considered
resectable based on SL, no laparotomy was performed
because of intercurrent medical unﬁtness or unresectability
on subsequent imaging. The median age of patients was 64
(range, 32–79) years, and the male-to-female ratio was
126:69 (65%).
2648 A. T. Ruys et al.Preoperative staging was extensive and included a CT,
abdominal US with Doppler, and direct cholangiography
by PTC or ERCP, in nearly all cases (Table 1). SL was
performed by an attending surgeon in 108 patients (62%),
and by a fellow or senior resident in 87 patients (38%). The
median time between SL and laparotomy was 37 (range,
14–90) days.
Surgical Findings
Staging laparoscopy was successfully performed in all
patients. Laparoscopic and ultimate ﬁndings are shown in
Fig. 1. Of all patients who underwent SL, 24 were found
unresectable, resulting in an overall yield of 14% (95%
conﬁdence interval (CI), 9–20). Patients (n = 10) who did
not undergo veriﬁcation by laparotomy were not included
in this calculation. Of all patients who were unresectable
(n = 76), 24 were identiﬁed by SL, resulting in an accu-
racy of 32% (95% CI, 18–40). Laparoscopy correctly
identiﬁed 59% (22/37) of patients with metastases (peri-
toneal or hepatic) but was hardly able to detect locally
advanced disease (2/17) or nodal metastases precluding a
curative resection (0/15). Final pathology showed benign
disease in 12 patients: chronic ﬁbrosing cholangitis
(n = 7), intraductal papillary mucinous neoplasm (n = 8),
primary sclerosing cholangitis (n = 1), chronic inﬂamma-
tion (n = 1), and IgG4-associated sclerosing cholangitis
(n = 1). A laparoscopic biopsy of suspicious lesions was
performed in 96 patients (58%). Based on these ﬁndings,
an unnecessary laparotomy was avoided in 24 patients. A
laparoscopic biopsy was performed in 15 patients who
were found unresectable at laparotomy. In six of these
patients, potentially detectable metastases (peritoneal or
hepatic) were present during laparotomy. The ﬁndings of
laparoscopic biopsies result in a sensitivity, speciﬁcity,
negative predictive value, and positive predictive value of
79, 100, 100, and 92%, respectively.
Minor complications (grade I and II) occurred in ﬁve
patients (3%), and included fever that required antibiotics
(n = 2), pain that required prolonged hospital stay (n = 1),
cardiac ischemia without elevation of cardiac enzymes
(n = 1), and pneumonia (n = 1). Complications were
likely to be related to the laparoscopic procedure, only in
the patients with pain, pneumonia, and cardiac ischemia.
No mortality occurred after laparoscopy. Complications
after laparotomy occurred in 17 patients (29%) with un-
resectable disease and included two major complications
([grade IIIa): wound dehiscence (n = 1), and abdominal
sepsis and death after a palliative gastrojejunostomy
(n = 1).
The median hospital stay for laparoscopy and laparot-
omy for patients with unresectable disease was 3 (range,
2–16) days and 14 (range, 4–86) days, respectively
(P\0.001). The time required until deﬁnitive internal
TABLE 1 Patient demographics and preoperative imaging studies
performed
Characteristics Patients (N = 195)
Male 126 (65%)
Female 69 (35%)
Age (range) Median 64 (32–79)
Bismuth-Corlette type
1 and 2 37 (19%)
3a 86(48%)
3b 45 (23%)
4 27 (14%)
SL performed by attending surgeon 108 (62%)
SL performed by senior resident or fellow 67 (38%)
Imaging performed
CT 189 (97%)
MRI 68 (35%)
US 195 (100%)
PTC/ERCP 194 (100%)
PET-CT 50 (26%)
FIG. 1 Patients with hilar cholangiocarcinoma treated surgically in
the Academic Medical Center from May 2000 to May 2010
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for unresectable patients.
Inﬂuencing Factors
Speciﬁc subgroups were further analyzed to identify
factors that inﬂuenced the yield and accuracy of SL. The
yield and accuracy of SL in the total group were 14 and
32%, respectively. The yield of SL during the time period
2000–2002 was 19% and seemed to decline to 16% in
2003–2006 and 7% in 2007–2010 (P = 0.13). The accu-
racy of the three time periods was 39, 30, and 18%,
respectively (P = 0.38). The yield and accuracy of dif-
ferent subgroups are shown in Table 2. Only preoperative
imaging, including PET-CT, showed a statistically signif-
icant decline in yield.
Missed Metastases and Positive Lymph Nodes
We further analyzed the group of patients with a negative
laparoscopy who were found unresectable during laparot-
omy.Thisgroupincludedpatientswith‘‘missedmetastases’’
(n = 15), positive lymph nodes (n = 21) beyond the hepa-
toduodenal ligament, and locally advanced disease
(n = 19). Of the metastases (hepatic and peritoneal), six
were suspicious during SL and were consequently biopsied.
Due to false-negative histological results, probably as a
result of inadequate sampling, these patients underwent a
laparotomy. Of all metastases, nine were [0.5 cm, sug-
gesting that these could have been detected by SL (Table 3).
Mostofthepositivelymphnodes(n = 10)wereencountered
around the common hepatic artery (Table 4). Twenty-one
positive lymph nodes were encountered, of which 13 could
be potentially reached by SL.
DISCUSSION
The present study has shown that the accuracy of SL for
suspected HCCA during the past decade in our department
was 32% and that the overall yield was 14%. In other
words, of all patients with HCCA who underwent a staging
laparoscopy, 14% was diagnosed with advanced disease
and could be spared an unnecessary laparotomy. Of all
HCCA patients with unresectable disease, 32% was
detected by laparoscopy.
The yield and accuracy of staging laparoscopy depend
on many different factors, including the a priori chance of
unresectable disease, the likelihood of ﬁnding unresecta-
bility, and the skills and determination of the surgeon
performing SL. The goal of staging laparoscopy is, in
TABLE 2 Factors possibly
inﬂuencing yield or accuracy of
SL in patients with HCCA
a Test for trend across groups
b Fisher’s exact test was used
instead of the Chi-square test
N Yield (%) P Accuracy (%) P
Entire group 175 14 32
Patients until 2003 50 18 39
Patients 2003–2006 64 16 0.13
a 30 0.37
a
Patients 2007–2010 61 8 26
Bismuth type 1–2 23 4 0.21
b 14 0.42
b
Bismuth type 3–4 152 15 34
SL performed by attending 108 15 0.59 34 0.62
SL performed by fellow or senior resident 67 12 29
PET-CT performed preoperatively 47 4 0.03
b 15 0.2
b
No PET-CT performed preoperatively 128 17 35
MRI performed preoperatively 63 18 0.36 44 0.13
No MRI performed preoperatively 112 12 26
TABLE 3 Liver and peritoneal metastases missed by SL (including
six patients with false-negative biopsies)
Duodenum Omentum Liver Diaphragm Total
\0.5 cm 1 5 6
[0.5 cm 2 1 3 3 9
TABLE 4 Positive lymph nodes found during laparotomy preclud-
ing a curative resection
Site of lymph nodes Patients (%) Potentially detectable
with extensive SL
Periportal 2 (1%) None
Common hepatic artery 10 (5%) Most
Pancreatic/duodenal 6 (3%) None
Celiac 3 (2%) All
Total 21 (11%)
2650 A. T. Ruys et al.particular, to exclude peritoneal metastases and small
liver metastases, for which other noninvasive tests lack
accuracy. Nonetheless, the overall yield and accuracy of
staging laparoscopy are calculated according to the pro-
portion of unresectable patients regardless of the cause of
unresectability. Hence, the yield of laparoscopy directly
depends on the proportion of patients with unresectable
disease detectable by laparoscopy, namely the patients
with peritoneal or hepatic metastases. This is important to
keep in mind, because during the past years the imaging
of HCCA patients has much improved. Accordingly,
patients with HCCA considered for treatment are better
staged, and consequently, a higher rate of patients is
diagnosed with unresectable disease by imaging without
the need for laparoscopy. Therefore, the patients who are
ultimately selected for laparoscopy are less likely to have
metastases and, in addition, have smaller metastases,
which are less likely to be detected by imaging or
laparoscopy.
The yield and accuracy of staging laparoscopy in
patients with HCCA found in the current study are con-
siderably lower than those reported in previous studies
(Table 5), including the study performed in our own
institution, which spanned the period 1992–2000. The most
likely explanations for these differences, as mentioned
earlier, include the better selection of patients for lapa-
roscopy, the impact of improved imaging, and the
decreased proportion of potentially detectable lesions by
laparoscopy (hepatic or peritoneal metastases). Further-
more, although HCCA is not known for its aggressive
course and rapid development of metastases, the time
between SL and deﬁnitive laparotomy may have inﬂuenced
results, because metastases could have developed in
between the two procedures.
The latest study to address the beneﬁt of laparoscopy in
HCCA included patients until 2004;
3 the other studies in
the literature are even less timely.
2,4,5,9 These time differ-
ences are important considering the impact of improved
imaging during past years. This is reﬂected by the pro-
portion of HCCA patients undergoing laparoscopy who
were ultimately resected. In the present study, 51% of all
HCCA patients undergoing laparoscopy underwent resec-
tion, as opposed to 27–45% reported in previous studies.
The proportion of metastases in the present study was 22%
(31/151), which is substantially lower than in previous
studies (29–33%). These factors are likely to have inﬂu-
enced the yield and accuracy found in this study. Last, 12
patients showed benign disease at ﬁnal pathology, and
because these patients obviously had no metastases, this
also inﬂuenced the yield.
The discrepancy with the results of our previous study is
striking, for which two additional reasons can be held
responsible. First, during the ﬁrst period, SL was combined
with a laparoscopic ultrasound examination as part of an
ongoing study evaluating the beneﬁt of SL and laparo-
scopic ultrasound.
13 As a consequence, more time was
spent on SL during the ﬁrst period, which also was more
extensive and performed with more dedication. Because
the previous study did not show any added value of lapa-
roscopic ultrasound, this procedure was abandoned during
SL in the subsequent series.
4 Second, during the ﬁrst period
there was uncertainty about the origin of the carcinoma—
gallbladder or hilar—in 20% of patients. During this per-
iod, these patients underwent SL, in which a gallbladder
carcinoma was ﬁnally diagnosed. Patients with gallbladder
cancer do have a high likelihood of metastatic disease, and
therefore the inclusion of this subset of patients has a
considerable impact on the amount of metastases found by
SL.
5,14 During the past period, we were able to make a
more accurate diagnosis based on preoperative, cross-sec-
tional imaging and only included patients with a high
suspicion of HCCA.
We could only identify a statistically signiﬁcant decline
in the yield of patients preoperatively staged with PET-CT
(Table 2). PET-CT is primarily performed to exclude
metastases, which also is the primary goal of SL, thus one
could expect this ﬁnding. Kim et al. found metastases in
7% of patients with the addition of PET-CT to the staging
protocol.
15 Statistical signiﬁcance directly depends on the
number of events in the two groups compared. The number
TABLE 5 Reported series of staging laparoscopy for hilar cholangiocarcinoma
Name Year No. of
patients
Yield (%) Accuracy (%) Patients with
metastases (%)
Metastases discovered
by SL (% of total metastases)
Patients
resected (%)
Tilleman et al.
4a 1993–2000 110 41 72 36 (33%) 31 (86%) 35 (32%)
Jarnagin et al.
5 1997–2001 56 25 42 16 (29%) 12 (75%) 23 (41%)
Connor et al.
2 1992–2003 84 24 53 28 (33%) 21 (75%) 20 (27%)
Goere et al.
3 2002–2004 20 25 45 NR NR 9 (45%)
This series 2000–2010 175 14 32 37 (22%) 22 (59%) 89 (51%)
a Also included gallbladder carcinomas
NR not reported
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was only 24 (14%). Hence, the current study, although by
far the largest to date, is probably underpowered to draw
valid conclusions regarding speciﬁc factors determining
yield and accuracy. Nonetheless, the yield and accuracy of
SL probably declined over time in our series, and PET-CT
and associated better staging might have further decreased
the added value of SL in HCCA patients. However, it
should be borne in mind that PET-CT was only performed
during the last period, therefore, these factors cannot be
analyzed independently. PET-CT also was not performed
in all patients during the last period, which introduces a
possible selection bias.
Although the yield and accuracy of SL were not clearly
higher when performed by an attending surgeon compared
with a senior resident or fellow, we believe that SL should
be performed by an experienced surgeon. We identiﬁed
several unresectable patients who could have been spared a
laparotomy with a more extensive SL. Twenty-one patients
were identiﬁed with distant positive lymph nodes pre-
cluding a curative resection at laparotomy. We believe that
there is room for improvement and that with extensive SL
with more attention for lymph nodes, an additional 13
patients (with positive nodes nearby the celiac trunk or
common hepatic artery) could have been identiﬁed with
positive lymph nodes during SL, improving the yield of SL
to 20% (Tables 4 and 5). Hence, the use of laparoscopic
ultrasound would have possibly increased yield and accu-
racy of lymph node assessment.
Finally, the beneﬁt of avoiding an unnecessary laparot-
omy with the associated morbidity and related increase in
hospital stay of 9 days in unresectable patients should be
weighed against the drawbacks of SL, namely morbidity
and hospital stay of SL, disadvantages of waiting time
between SL and laparotomy, operating time, and healthcare
costs. This study questions the conclusion of previous
studies, including our own published in 2002, that patients
with HCCA should undergo SL routinely.
2–5,9 In the light
of our recent results, we have reconsidered the place of SL
in our workup of patients with HCCA. Several options may
be considered, including:
1) A more selective approach to submitting patients with
HCCA for SL, including only patients with Bismuth
type 3 and 4 tumors, and patients with suspicion on
metastases;
2) The use of SL as a short procedure preceding
laparotomy in one session. This setup requires ﬂexi-
bility of the operation schedule while one needs to be
prepared to convert to laparotomy and an extensive
resection when SL proves negative;
3) Application of SL as a protocol performed by dedi-
cated (staff) surgeons experienced in laparoscopic
procedures. A standard checklist will improve the
accuracy of SL and call for detail in the sampling of
distant lymph nodes.
In conclusion, accurate staging of patients with HCCA
remains difﬁcult. SL avoided an unnecessary laparotomy in
14% of patients after complete imaging, with an accuracy
of 32%. It is likely that these numbers will even further
decline with the use of more sophisticated imaging tech-
niques. In contrast to previous reports, the results of the
present study do not justify the routine use of SL in patients
with resectable HCCA. The place of SL in the workup of
patients with HCCA needs to be reconsidered, and one
should decide whether the declining additional value of SL
outweighs the drawbacks of SL.
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